Ovarian cancer: An analysis of forty-four patients at the National Radiotherapy Centre, Accra-Ghana

West African Journal of Medicine

Volumn 26, Issue 2, 2007, Pages 93-96

  Vanderpuye, V ^a   Yarney, J ^a  

^a KORLE BU TEACHING HOSPITAL   (Ghana)

Author keywords

Chemotherapy; Ghana; Ovarian cancer; Tumour markers

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GERM CELL TUMOR; GHANA; GYNECOLOGICAL RADIOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; ONSET AGE; OUTCOME ASSESSMENT; OVARY CANCER; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CISPLATIN; CYCLOPHOSPHAMIDE; FEMALE; GHANA; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL; TREATMENT OUTCOME;

EID: 34848863653     PISSN: 0189160X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Rubin SC, Sabbatini P, Randal ME. In cancer Management: A multidisciplinary Approach. Ovarian Cancer. pp 495 - 481. 7th Edition. Publisher, The Oncology Group 2003.
2. Young RC, Walton LA, Ellenberg SS. Adjuvant Therapy in Stage 1 and 2 epithelial ovarian cancer: results of two prospective randomized trials. N Eng J Med 1990; 322: 1021-1027.
3. Lambert HE, Thomas H. Soutter WP. In Pat Price, K Sikora (Editors)., Treatment of Cancer. Chapter 33. Ovary and Fallopian tube. Pg 707-7234th Edition. Publishers Anorld UK 2002.
4. Canistra SA. Cancer of the Ovary. Medical Progress. Review article. N Eng. J Med; 351: 2519-3529.
5. Thomas F. M. In Radiation Oncology. Rationale. Technique. Results Chapter 31. The Ovary. 8th Edition. Editors: JD Cox, KK. Ang, Pg. 759. Publishers Mosby 2003.
6. Omura GA, Brachy MF, Homesley AD et al. Long term follow up and Prognosis factor analysis in advanced ovarian carcinoma; A GOG experience. J Clin Oncol 1991; 9: 1138-1150
7. McGuire WP, Hoskins WJ, Brady MF Cyclophosphomide and Cisplatin compared with Paclitaxel and Cisplatin in patients with stage III and IV ovarian cancer. N. Engl J Med 1996; 334: 1-6.
8. Meyer J, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. British J Cancer 2000; 82: 1535-1538.
9. Van Nagel JR Jnr, Ureland FR. Ultrasound evaluation of pelvic masses; Predictors of Malignancy for the general gynaecologist. Cur opin. obstet gynaecol 1999; 11:45-49.
10. Karlan BY, Markman MA, Eifel PJ. In Cancer. Principles and practice of oncology. Chapter 32 section 4. Ovarian Cancer. Pg 1376. 7th edition. Devita DT Jnr, Hellman S, Rosenburg SA (editors) Publishers Lippincott Willam Raven. 2005
11. Piccart MJ, Bertelsen K. James K et al. Randomized intergroup trial of Cisplatin-paclitaxel vrs cisplatin-cyclophosphomide in woman with advanced epithelial ovarian cancer; three year results. J Natl Cancer Inst 2000; 92: 699-708.
12. Bristow RE, Tomacruz RS, Amstrong DK Survival effects of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a mete-analysis. J Clin Oncol 2002; 20: 1248-1259.
13. Hoskin WJ, MC, Guire WP, Brady MF. The effects of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J obstet Cynaecol 1994; 170: 974-980.
14. Staging classification and clinical practice guidelines of gynaecological cancers. Figo committee on Gynaecological oncology and IGCS guidelines Committee. Ovarian Cancer pp. 95 - 115. Ed. Benedet JL, Hacker NF, Ngan NYS. Publishers Ushers Print and Design.
15. Van de Burg MEL, Van Lent M, Buyse M The effect of debulking surgery after inductive chemotherapy on the Prognosis in advanced ovarian cancer. N Eng J Med 1995; 332: 629-34.
16. Rose PG, Nerenstone S, Brady MF. A phase III randomized study of interval secondary cytoreduction in patients with suboptimal residual disease: a Gynaecologic oncology group study. Prog Proc. Am Soc Clin oncol 2002: 21-201a.
17. Muggia FM, Braly PS, Brady MF. Phase 3 randomised study of cisplatin versus paclitaxel versus cisplatin-paclitaxel in patients with suboptimal stage 3 and 4 ovarian cancer. A GOG Study. J Clin Oncol 2002; 18: 106-115.
18. DiSaia P, Creaseman W. Epithelial Ovarian Cancer. Clinical Gynaecologic Oncology. 6th Eds:289-530.Mosby 2002.